{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "HKD", "marketState": "CLOSED", "exchangeTimezoneShortName": "HKT", "gmtOffSetMilliseconds": 28800000, "esgPopulated": false, "regularMarketChangePercent": -4.999998, "regularMarketPrice": 14.06, "exchange": "HKG", "shortName": "ALPHAMAB-B", "longName": "Alphamab Oncology", "messageBoardId": "finmb_591593901", "exchangeTimezoneName": "Asia/Hong_Kong", "market": "hk_market", "regularMarketTime": 1683878916, "regularMarketDayHigh": 15.0, "regularMarketDayRange": "13.96 - 15.0", "regularMarketDayLow": 13.96, "regularMarketVolume": 7759000, "regularMarketPreviousClose": 14.8, "bid": 14.04, "ask": 14.06, "fullExchangeName": "HKSE", "financialCurrency": "CNY", "regularMarketOpen": 15.0, "averageDailyVolume3Month": 5781755, "averageDailyVolume10Day": 3165541, "fiftyTwoWeekLowChange": 8.610001, "fiftyTwoWeekLowChangePercent": 1.5798167, "fiftyTwoWeekRange": "5.45 - 17.7", "fiftyTwoWeekHighChange": -3.6400003, "fiftyTwoWeekHighChangePercent": -0.20564973, "fiftyTwoWeekLow": 5.45, "fiftyTwoWeekHigh": 17.7, "earningsTimestamp": 1680273378, "earningsTimestampStart": 1680273378, "earningsTimestampEnd": 1680273378, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.38, "epsForward": -0.34, "epsCurrentYear": -0.43, "priceEpsCurrentYear": -32.697674, "sharesOutstanding": 964716032, "bookValue": 1.663, "fiftyDayAverage": 14.9652, "fiftyDayAverageChange": -0.9052, "fiftyDayAverageChangePercent": -0.060486995, "twoHundredDayAverage": 10.558, "twoHundredDayAverageChange": 3.5020008, "twoHundredDayAverageChangePercent": 0.33169168, "marketCap": 13600576512, "forwardPE": -41.352943, "priceToBook": 8.4546, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1576114200000, "priceHint": 3, "regularMarketChange": -0.7399998, "symbol": "9966.HK"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "No. 175 Fangzhou Road", "address2": "Suzhou Industrial Park", "city": "Suzhou", "country": "China", "phone": "86 512 6285 0800", "website": "https://www.alphamabonc.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for neoadjuvant treatment of HER2-positive breast cancer and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial for auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for advanced solid tumors with deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III clinical trials for biliary tract cancer. In addition, its product pipeline also includes KN052, a PD-L1/OX40 bispecific antibody, which is in phase I clinical trial for the treatment of advanced solid tumors; and JSKN003, a biparatopic HER2-targeting antibody-drug conjugate that is in phase Ia/Ib clinical trial for the treatment of advanced malignant solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.", "fullTimeEmployees": 472, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ting  Xu Ph.D.", "age": 49, "title": "Founder, Exec. Chairman & CEO", "yearBorn": 1973, "fiscalYear": 2021, "totalPay": {"raw": 966977, "fmt": "966.98k", "longFmt": "966,977"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 13912545, "fmt": "13.91M", "longFmt": "13,912,545"}}, {"maxAge": 1, "name": "Ms. Yang  Liu", "age": 50, "title": "VP of Corp. Operations & Exec. Director", "yearBorn": 1972, "fiscalYear": 2021, "totalPay": {"raw": 427895, "fmt": "427.89k", "longFmt": "427,895"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 3102508, "fmt": "3.1M", "longFmt": "3,102,508"}}, {"maxAge": 1, "name": "Ms. Jin'nan  Wang", "age": 39, "title": "Director of Investor Relations & Joint Company Sec.", "yearBorn": 1983, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Yumin  Wan", "age": 50, "title": "VP of Gov. Affairs & PR", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mike  Liu M.B.A., Ph.D.", "age": 56, "title": "Sr. VP of Bus. Devel.", "yearBorn": 1966, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jing  Han", "age": 48, "title": "Chief Commercial Officer", "yearBorn": 1974, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lok Yee  Chan A.C.I.S., A.C.S.", "age": 32, "title": "Joint Company Sec.", "yearBorn": 1990, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}